Bioavailability
Conditions
Keywords
β-alanine
Brief summary
The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).
Detailed description
Subjects will consume 10 g of β-alanine one day by 4 ingestions of 2.5 g separated by 1 hour and 15 min. While on another day 20 g of β-alanine by 4 ingestions of 5 g separated by 1 hour and 15 minutes, with a washout period of 15 days between the two doses. Subsequently, the amino acid levels in blood will be analyzed after the product intake and during a period of 8 hours. Each day of visit the paresthesias (moment of appearance, intensity and sensations) will be studied at different times.
Interventions
Sponsors
Universidad Católica San Antonio de Murcia
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Men between 18 and 60 years old. * Cyclists with more than two years of cycling experience. * Bicycle training at least twice a week.
Exclusion criteria
* Suffer a lasting injury that prevents you from training in the month prior to surgery. * Subjects with a chronic illness. * Having consumed in the three months prior to the start of the study any β-alanine supplement. * Making changes in diet or exercise during the study. * Inability to understand the informed consent form. * Consumption of other supplements that could alter the results of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aminoacids in plasma | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. | The complete series of amino acids will be analyzed in plasma, after supplement intake, for 8 hours and at various times after product intakes. A bioavailability curve will be developed for each of these samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Paresthesia | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. | It will be recorded by means of a visual analog scale (VAS), drawn with a continuous line of 10 centimeters where the left edge determines no unusual sensation, translated to 0 in the recording of the data; and on the right edge more intense sensation, translated to 10. |
| symptomatology - qualitative question | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. | They should answer if they have felt at any time after the ingestion of β-alanine any symptomatology such as: prickling, itching, tingling, numbness, chills and pain. |
Countries
Spain
Outcome results
None listed